Legend Biotech presented first-in-human data for LB-2501, a CD19/CD20 dual-targeting off-the-shelf CAR T, at EHA2026. Across 12 treated participants with relapsed or refractory B-cell non-Hodgkin lymphoma, the company reported responses at both dose levels, with all six higher-dose patients responding and five achieving complete responses. Legend said the highest adverse event grade observed so far was grade two, and there has been no neurotoxicity reported to date—an early signal aimed at enabling outpatient dosing without lymphodepletion. Separate EHA updates for Kelonia’s BCMA-targeting KLN-1010 also reported high response rates and MRD-negative status in available patients.